Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy

The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess its value as a biomarker for diagnostic typing, disease severity, and prognosis in MSA.

Inclusion Criteria:

• Age> 35 years old, gender is not limited;
• Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
• all patients had been ruled out of polyQ disease by genetic testing;
• Voluntarily participate in this study and sign the informed consent form.

Exclusion Criteria:

• pregnancy or breastfeeding;
• contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
• previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
• History of alcohol or drug abuse